



Year Ended March 31, 2012

Contact:

Corporate Communication Group Tel: 06-6321-7007 Fax: 06-6321-7086 E-mail: ir@santen.co.jp Stock Code: 4536

Contents

inancial highlights		2
	Consolidated financial summary	2
		2
	Consolidated financial indexes	2
Exchange rates Consolidated information Consolidated statements of income and comprehensive income Consolidated statements of income details Major Selling, general and administrative expenses Major Non-operating income and expenses Sales details Sales details Sales of major prescription pharmaceuticals Consolidated balance sheets Assets Liabilities and net assets Consolidated information Other consolidated information Br&D expenditures Capital expenditures Capital expenditures Capital expenses Number of employees Reference information Research & development Pharmaceutical market in Japan Pharmaceutical market in Japan Revision of National Health Insurance (NHI) drug prices Market shares		
onsolidated informati	on	4
	Consolidated statements of income and comprehensive income	4
	Consolidated statements of income details	5
	■ Major Selling, general and administrative expenses	5
		5
	Sales details	6
	Sales by segment	6
	Sales of major prescription pharmaceuticals	7
		9
	Assets	9
	Liabilities and net assets	10
	Consolidated statements of cash flows	11
	Other consolidated information	12
	R&D expenditures	12
	· · · · ·	12
		12
		12
	■ Number of employees	12
ference information		13
	Research & development	13
	Pipeline of prescription pharmaceuticals (Clinical trials)	13
	Changes from February 7, 2012	14
	Pharmaceutical market in Japan	15
	Revision of National Health Insurance (NHI) drug prices	15
		15
	Market shares by therapeutic area - prescription ophthalmics	15
	Stock information	16
	Stock price	16
	Major shareholders	16
	Major stock information	16
	Breakdown of shareholding by number of shares	17
	Breakdown of shareholding by number of shareholders	17
	Consolidated subsidiaries	18
		19

Forecasts in this report are based on the currently available information.

Actual results may differ materially depending on a number of factors including adverse economic conditions, delays in new products launch, currency exchange rate, legislative and regulatory developments.



■Consolidated financial summary

Consolidated financial summa	Consolidated financial summary										
Year ended March 31	2008	2009	2010	2011	2012	% Change 2012/2011	2013 Forecast	% Change 2013/2012			
Net sales	103,394	101,618	110,594	110,812	114,416	3.3	114,500	0.1			
Operating income	20,370	15,494	29,640	30,738	26,733	-13.0	23,500	-12.1			
Ordinary income	20,702	15,935	29,862	31,484	27,780	-11.8	24,000	-13.6			
Net income	12,650	10,123	18,722	21,333	17,160	-19.6	16,000	-6.8			
Dividends per share (yen)	80	80	80	90	100	_	100				
DOE (%)	5.4	5.4	5.2	5.3	5.4						

Consolidated balance sheets summary

(Millions of yen) % Change 2008 2009 2010 2011 2012 Year ended March 31 2012/2011 Total assets 156,547 151,012 166,878 184,801 198,801 7.6 127,118 125,368 137,603 156,404 164,861 5.4 Net assets Interest-bearing debts 5,278 699 617 188 157 -16.6

Consolidated financial indexes

Year ended March 31	2008	2009	2010	2011	2012	% Change 2012/2011	2013 Forecast	% Change 2013/2012
EPS (yen)	146.15	119.08	220.10	249.71	196.96	-21.1	183.64	-6.8
BPS (yen)	1,494.48	1,472.32	1,614.08	1,793.15	1,887.81	5.3	_	—
Debt equity ratio (times)	0.04	0.01	0.00	0.00	0.00	—	_	_
PER (times)	15.9	23.0	12.7	13.3	17.9	—	_	_
PBR (times)	1.56	1.86	1.74	1.85	1.87	—	_	—
ROE (%)	9.9	8.00	14.3	14.5	10.7	—	—	_
ROA (%)	8.0	6.6	11.8	12.1	8.9	—	—	_
Equity ratio(%)	81.1	82.9	82.3	84.5	82.8	—	_	_
Free cash flows (millions of yen)	12,316	8,896	24,795	16,118	18,203	12.9	_	_
EBITDA (millions of yen)	25,172	20,098	32,084	34,087	30,601	-10.2	_	_

*Free cash flows = (Cash flows from operating activities) - (Capital expenditures)

Not adjusting increase/decrease in trade receivables for fiscal years ending on holidays.


*EBITDA = (Income before income taxes) + (Interest expense) + (Depreciation and amortization)


Exchange rates								
	2008.3	2009.3	2010.3	2011.3	2012.3	2013.3 Forecast		
Exchange rate: US dollar	114.29	100.81	92.79	85.57	79.03	79.00		
: Euro	161.98	146.71	131.12	113.45	110.27	104.00		
: RMB	_	14.86	13.70	12.94	12.34	12.50		


Forecasts in this report are based on the currently available information. Actual results may differ materially depending on a number of factors including adverse economic conditions etc.


Financial highlights


Net sales (Millions of yen) 115,000 110,000 105,000 90,000 85,000 2008 2009 2010 2011

















Consolidated Financial summary (Graph)

Consolidated information Consolidated statements of income and comprehensive income



					(Mi	llions of yen)
Year ended March 31	2008	2009	2010	2011	2012	% Change 2012/2011
Net sales	103,394	101,618	110,594	110,812	114,416	3.3
Cost of sales	36,513	35,947	34,710	34,436	35,385	2.8
(Percentage of net sales)	35.3%	35.4%	31.4%	31.1%	30.9%	
Gross profit	66,880	65,671	75,884	76,375	79,031	3.5
(Percentage of net sales)	64.7%	64.6%	68.6%	68.9%	69.1%	
Selling, general and administrative expenses	46,510	50,177	46,244	45,636	52,298	14.6
(Percentage of net sales)	45.0%	49.4%	41.8%	41.2%	45.7%	
R&D expenditures	12,941	18,457	14,123	13,221	17,225	30.3
(Percentage of net sales)	12.5%	18.2%	12.8%	11.9%	15.1%	
Operating income	20,370	15,494	29,640	30,738	26,733	-13.0
(Percentage of net sales)	19.7%	15.2%	26.8%	27.7%	23.4%	
Non-operating income	1,356	1,430	842	1,011	1,119	10.6
Non-operating expenses	1,024	989	620	265	71	-73.1
Ordinary income	20,702	15,935	29,862	31,484	27,780	-11.8
(Percentage of net sales)	20.0%	15.7%	27.0%	28.4%	24.3%	
Extraordinary gain	237	18	74	15	61	307.3
Extraordinary loss	457	129	1,327	425	51	-87.9
Income before income taxes	20,482	15,823	28,610	31,074	27,791	-10.6
(Percentage of net sales)	19.8%	15.6%	25.9%	28.0%	24.3%	
Income taxes - current	8,145	8,269	10,687	9,970	9,912	-0.6
Income taxes - deferred	-313	-2,568	-800	-229	717	-413.2
Income before minority interests	—	—	—	21,333	17,160	-
Net income	12,650	10,123	18,722	21,333	17,160	-19.6
(Percentage of net sales)	12.2%	10.0%	16.9%	19.3%	15.0%	
Income before minority interests	_	_	_	21,333	17,160	_
Other comprehensive income	—	—	—	-1,537	-194	_
Comprehensive income	_	_	_	19,796	16,966	_

Consolidated statements of income details

■Major Selling, general and administrative expenses Year ended March 31 2008 2010 2011 2012 2009 2012/2011 Personnel expenses 13,220 13,089 13,347 13,612 14,933 Sales promotion expenses 4,184 4,084 4,172 4,490 5,163 Royalty expenses 2,211 2,116 2,497 2,545 1,952 Advertising expenses 2,671 1,878 1,637 1,500 1,221 R&D expenditures 12,941 18,457 14,123 13,221 17,225

■Major Non-operating income and expenses

Year ended March 31	2008	2009	2010	2011	2012	% Change 2012/2011
Interest and dividend income	606	548	417	521	528	1.3
Gain on insurance received	—	_	128	136	143	4.8
Interest expense	96	65	52	36	22	-37.9

(Millions of yen)

(Millions of yen)

% Change

9.7

15.0

-23.3

-18.6

30.3

Sales details



■Sales by segment

Sales by segment (Millions									
Year ended March 31	2008	2009	2010	2011	2012	% Change 2012/2011			
Pharmaceuticals	102,952	100,970	109,057	108,575	111,846	3.0			
Prescription pharmaceuticals	97,500	95,745	103,806	103,852	107,249	3.3			
Ophthalmic	85,426	84,488	86,867	90,797	93,620	3.1			
Anti-rheumatic drugs	9,626	9,741	9,907	9,833	9,987	1.6			
Other prescription pharmaceuticals	2,447	1,515	7,030	3,221	3,641	13.0			
OTC pharmaceuticals	5,451	5,225	5,251	4,723	4,597	-2.7			
Others	442	648	1,537	2,236	2,570	14.9			
Medical devices	414	624	1,520	2,224	2,558	15.0			
Others	27	24	16	11	11	2.1			
Total net sales	103,394	101,618	110,594	110,812	114,416	3.3			

[Domestic]

[Domestic]					(Mil	llions of yen)
Year ended March 31	2008	2009	2010	2011	2012	% Change 2012/2011
Pharmaceuticals	88,138	87,972	88,605	91,047	93,449	2.6
Prescription pharmaceuticals	82,707	82,754	83,372	86,332	88,862	2.9
Ophthalmic	72,319	72,357	72,666	75,585	77,753	2.9
Anti-rheumatic drugs	9,519	9,634	9,772	9,727	9,883	1.6
Other prescription pharmaceuticals	868	762	933	1,020	1,225	20.0
OTC pharmaceuticals	5,430	5,218	5,232	4,715	4,587	-2.7
Others	428	647	980	1,501	1,924	28.1
Medical devices	401	622	963	1,490	1,912	28.3
Others	27	24	16	11	11	2.1
Total domestic sales	88,566	88,620	89,586	92,549	95,374	3.1
(Percentage of total net sales)	85.7%	87.2%	81.0%	83.5%	83.4%	_

[Overseas]

					(initiality of year				
Year ended March 31	2008	2009	2010	2011	2012	% Change 2012/2011			
Pharmaceuticals	14,813	12,997	20,451	17,527	18,396	5.0			
Prescription pharmaceuticals	14,793	12,990	20,433	17,519	18,386	4.9			
Ophthalmic	13,106	12,131	14,201	15,211	15,866	4.3			
Anti-rheumatic drugs	107	106	135	106	103	-3.1			
Other prescription pharmaceuticals	1,579	752	6,096	2,200	2,416	9.8			
OTC pharmaceuticals	20	6	18	8	10	24.3			
Others	13	1	556	734	645	-12.1			
Medical devices	13	1	556	734	645	-12.1			
Others	_			_	_	—			
Total overseas sales	14,827	12,998	21,008	18,262	19,042	4.3			
(Percentage of total net sales)	14.3%	12.8%	19.0%	16.5%	16.6%	—			


(Millions of yen)

Sales details

Therapeutic category	Generic name/formulation	Brand name	Region	Launched
Bacterial conjunctivitis	levofloxacin/ophthalmic solution	Cravit	Japan	Apr-00
Bacteriai conjunctivitis	ofloxacin/ophthalmic solution	Tarivid	Japan	Sep-87
	tafluprost/opthalmic solution	Tapros	Japan	Dec-08
	dorzolamide hydrochloride-timolol maleate/	Cogant	Ionon	Jun-10
	combination ophthalmic solution	Cosopt	Japan	Juli-10
Glaucoma	timolol maleate/ophthalmic solution	Timoptol	Japan	Sep-81
Glaucollia	timotol maleate/	Timontal VE	Ionon	Nov-99
	long-acting ophthalmic solution	Timoptol XE	Japan	1107-99
	bunazosin hydrochloride/opthalmic solution	Detantol	Japan	Sep-01
	isopropyl unoprostone/opthalmic solution	Rescula 💥	Japan	Oct-94
Allergy	levocabastine hydrochloride/	Livostin	Ionon	Jan-01
Allergy	ophthalmic solution	Livostin	Japan	Jall-01
Corneal disease	sodium hyaluronate/ophthalmic solution	Hyalein	Japan	Jun-95
Comear disease	diquafosol sodium	Diquas	Japan	Dec-10
Inflammation	fluorometholone/ophthalmic solution	Flumetholon	Japan	Oct-75
Senile cataract	pirenoxine/ophthalmic solution	Kary Uni	Japan	Jul-92
Adjuvant for ophthalmic	sodium hyaluronate/	Onegan II:	Ionon	Ion 05
operations	adjuvant for ophthalmic operations	Opegan Hi	Japan	Jan-95
	bucillamine/tablet	Rimatil	Japan	Sep-87
Rheumatoid arthritis	salazosulfapyridine/enteric coated tablet	Azulfidine EN	Japan	Dec-95
	methotrexate/tablet	Metolate	Japan	Jul-04


■Sales of major prescription pharmaceuticals

* Rescula: This product, which was launched in October 1994, has been sold by Santen Pharmaceutical Co., Ltd. since October 2004.





(Millions of yen)								
	1	r ended March 3	Yea		31	ended March	Year e	
Brand name	% Change 2013/2012	2013 Forecast	% Change 2012/2011	2012	2011	2010	2009	2008
Cravit	-2.4	12,075	-4.2	12,368	12,904	12,240	12,443	12,864
Tarivid	-18.4	1,577	-20.1	1,932	2,419	2,423	2,488	3,139
Tapros	9.9	8,076	10.8	7,351	6,633	4,687	1,058	_
Cosopt	38.1	8,661	113.7	6,271	2,935	_	_	_
Timoptol	-32.5	1,148	-20.9	1,701	2,152	2,832	3,213	3,574
Timoptol XE	-22.8	1,856	-16.9	2,404	2,891	3,475	3,477	3,432
Detantol	-9.1	1,789	-4.7	1,968	2,064	2,168	2,283	2,337
Rescula	-4.9	2,351	-11.0	2,472	2,777	3,669	4,386	4,880
Livostin	1.7	3,404	-11.9	3,346	3,800	3,229	4,302	4,341
Hyalein	-8.0	20,443	4.5	22,216	21,257	21,219	20,030	19,521
Diquas	86.2	5,299	281.7	2,846	745	_	_	_
Flumetholon	-4.1	3,904	-14.3	4,072	4,753	4,432	4,671	4,821
Kary Uni	4.3	3,849	-1.0	3,690	3,728	3,728	3,572	3,652
Opegan Hi	2.3	3,086	-6.5	3,018	3,226	3,431	3,236	3,204
Rimatil	-12.6	3,211	-6.9	3,673	3,944	4,352	4,539	4,767
Azulfidine EN	-5.2	3,818	-1.9	4,030	4,106	4,216	4,187	4,121
Metolate	9.0	1,859	36.4	1,705	1,250	995	797	622



Forecasts in this report are based on the currently available information. Actual results may differ materially depending on a number of factors including adverse economic conditions etc.

Consolidated balance sheets

Assets									(Millions o	<i>,</i>
Year ended March 31	2008		2009		2010	1	2011		2012	
		%		%		%		%		%
Current assets	102,754	65.6	101,053	66.9	118,832	71.2	137,668	74.5	140,288	70.6
Cash and deposits	35,483		37,117		56,677		65,558		66,235	
Notes and accounts receivable-trade	35,614		36,011		35,268		38,980		37,923	
Marketable securities	15,868		11,396		8,998		13,332		12,739	
Inventories	11,332		12,235		13,623		14,704		17,949	
Deferred tax assets	1,699		1,941		2,166		1,986		1,921	
Other current assets	2,757		2,352		2,098		3,106		3,521	
Allowance for doubtful receivables	-1		-1		-0		-1		-1	
Fixed assets	53,548	34.2	49,959	33.1	48,046	28.8	47,133	25.5	58,513	29.4
Tangible assets	29,848	19.1	28,664	19.0	26,574	15.9	24,956	13.5	25,523	12.8
Buildings and structures	15,160		15,864		14,622		13,450		12,806	
Machinery, equipment and vehicles	2,656		2,432		1,994		1,632		1,581	
Land	8,558		8,678		8,418		8,216		8,213	
Lease assets	—		39		97		186		166	
Construction in progress	1,879		99		43		186		1,365	
Other tangibles	1,594		1,550		1,397		1,283		1,390	
Intangible assets	2,233	1.4	1,549	1.0	1,231	0.7	991	0.5	12,877	6.5
Goodwill	300		_		_		_		5,801	
In–process research and development	_		_		_		_		5,941	
Software	1,602		1,355		1,158		952		831	
Other intangibles	330		193		72		39		301	
Investments and other assets	21,466	13.7	19,744	13.1	20,240	12.1	21,185	11.5	20,112	10.1
Investment securities	16,949		11,818		12,239		12,141		12,411	
Deferred tax assets	1,822		6,409		6,702		7,538		6,500	
Other assets	2,694		1,516		1,299		1,505		1,200	
Deferred assets	244	0.2	_	_	_	_	_	_	_	_
Total assets	156,547	100.0	151,012	100.0	166,878	100.0	184,801	100.0	198,801	100.0



■Liabilities and net assets

Liabilities and net as	sets								(Millions o	of yen)
Year ended March 31	2008		2009		2010		2011		2012	
		%		%		%		%		%
Current liabilities	26,561	17.0	22,439	14.9	25,286	15.2	24,104	13.0	27,425	13.8
Trade accounts payable	5,633		6,018		5,600		6,031		8,074	
Short-term debt	—		545		543		—		—	
Current portion of long- term debt	5,168		110		—		—		5	
Other payables	7,690		7,414		7,936		8,444		9,009	
Income taxes payable	4,323		4,163		6,618		4,631		5,282	
Reserve for bonuses	2,612		2,590		2,687		2,712		2,943	
Other reserves	74		69		81		87		81	
Other current liabilities	1,057		1,528		1,819		2,198		2,027	
Non-current liabilities	2,867	1.8	3,203	2.1	3,988	2.4	4,292	2.3	6,514	3.3
Long-term debt	110		_		_		_		_	
Lease Obligations	—		43		74		152		115	
Deferred tax liabilities	17		20		15		20		1,996	
Retirement and severance benefits	1,815		2,393		2,910		3,266		3,459	
Retirement and severance benefits for directors and	487		505		456		453		222	
auditors										
Asset retirement obligations	-		_		_		160		161	
Other liabilities	437		240		531		238		559	
Total liabilities	29,429	18.8	25,643	17.1	29,275	17.5	28,397	15.4	33,940	17.1
Shareholders' equity	126,398	80.7	129,808	86.0	141,866	85.0	162,159	87.7	170,770	85.9
Common stock	6,418	4.1	6,457	4.3	6,538	3.9	6,614	3.6	6,694	3.4
Capital surplus	7,113	4.5	7,152	4.7	7,233	4.3	7,968	4.3	8,049	4.0
Retained earnings	117,786	75.2	121,133	80.2	133,053	79.7	147,578	79.9	156,030	78.5
Treasury stock, at cost	-4,920	-3.1	-4,934	-3.3	-4,958	-3.0	-1	-0.0	-4	-0.0
Accumulated other	600	0.4	-4,628	-3.1	-4,524	-2.7	-6,061	-3.3	-6,255	-3.1
comprehensive income	000	0.4	-4,020	-3.1	-4,524	-2.1	-0,001	-3.5	-0,235	-3.1
Unrealized gains on	2,273	1.5	-246	-0.2	136	0.1	-443	-0.2	51	0.0
securities, net of taxes	2,275	1.5	-240	-0.2	150	0.1	-++5	-0.2	51	0.0
Foreign currency	-1,673	-1.1	-4,381	-2.9	-4,660	-2.8	-5,618	-3.0	-6,306	-32
translation adjustments										
Stock subscription rights	119	0.1	188	0.1	260	0.2	305	0.2	347	0.2
Total net assets	127,118	81.2	125,368	82.9	137,603	82.5	156,404	84.6	164,861	82.9
Total liabilities and										
net assets	156,547	100.0	151,012	100.0	166,878	100.0	184,801	100.0	198,801	100.0

Consolidated statements of cash flows

Year ended March 31	2008	2009	2010	2011	2012
rear ended March 51	2008	2009	2010	2011	2012
I . Cash flows from operating activities:					
Income before income taxes	20,482	15,823	28,610	31,074	27,791
Depreciation and amortization	4,593	4,209	3,421	2,976	2,949
Loss on impairment of fixed assets	316	—	397	-	19
Increase/decrease in retirement and severance benefits	411	553	517	359	178
Interest and dividend income	-606	-548	-417	-521	-528
Interest expense	96	65	52	36	22
Equity in losses of affiliates	—	679	564	-	-
Increase/decrease in trade receivables	-586	-916	698	-3,892	1,03
Increase/decrease in inventories	-1,005	-1,334	-1,438	-1,299	-3,294
Increase/decrease in trade accounts payable	-430	509	-248	521	2,03
Other, net	-561	759	1,872	-11	Ģ
Subtotal	22,710	19,801	34,030	29,243	30,21
Interest and dividend income received	610	550	418	513	54
Interest expense paid	-94	-71	-46	-36	-1
Income taxes paid	-7,758	-8,431	-8,291	-11,951	-9,26
Net cash provided by operating activities	15,468	11,849	26,110	17,769	21,48
· · · ·					
I . Cash flows from investing activities:					
Increase in fixed deposits	-1,518	-4,420	-2,236	-4,384	-16
Decrease in fixed deposits	2,160	3,358	1,937	3,519	2,78
Payments for acquisition of marketable securities	_	_	-3,599	-1,488	-1.61
Proceeds from sale of marketable securities	1,000	_	5,098	403	4,85
Payments for acquisition of fixed assets	-3.151	-2,953	-1,314	-1,650	-3,28
Proceeds from sale of fixed assets	5	2	2	188	-,
Purchase of investment securities	-3.266	-2,080	-1,027	-4.296	-2.42
Proceeds from sale of investment securities	2,660	462	309	20	37
Payment for acquisition of shares of subsidiaries due to	2,000		207	_0	
change in consolidation	_	_	_	-	-10,80
Payments for loans	_	-300	-49	-0	
Proceeds from loans	_	311	49	-0	
Other, net	27	0	49	13	
Net cash(used in) provided by investing activities	-2,083	-5,619	-829	-7,676	-10,27
Net cash(used iii) provided by investing activities	-2,085	-5,019	-029	-7,070	-10,27
I. Cash flows from financing activities:					
Proceeds from short-term debt	_	545	548	258	_
Repayment of short-term debt	_	545	-520	-776	
	169	5 169		-//0	
Repayment of long-term debt	-168	-5,168	-110	25	
Purchase of treasury stock	-4,815	-15	-24	-25	-
Proceeds from disposal of treasury stock	0	1	0	5,641	9.70
Dividends paid	-6,505	-6,798	-6,803	-6,808	-8,70
Other, net	72	61	156	139	14
Net cash provided by financing activities	-11,415	-11,373	-6,753	-1,570	-8,55
V. Effect of exchange rate changes on cash	-140	-569	-135	-388	-9
and cash equivalents					
V. Net increase/decrease in cash and cash equivalents	1,828	-5,713	18,392	8,133	2,55
VI. Cash and cash equivalents at beginning of year	49,841	51,669	45,956	64,348	72,48
🗷. Cash and cash equivalents at end of year	51,669	45,956	64,348	72,482	75,03

Other consolidated information



■R&D expenditures					(Mill	ions of yen)
Year ended March 31	2008	2009	2010	2011	2012	2013 Forecast
Consolidated	12,941	18,457	14,123	13,221	17,225	17,500
Percentage of net sales	12.5%	18.2%	12.8%	11.9%	15.1%	15.3%

Capital expenditures

Capital expenditures					(N	fillions of yen)
Year ended March 31	2008	2009	2010	2011	2012	2013 Forecast
Consolidated	2,758	2,744	1,228	1,709	3,492	6,430

Note: Includes investment in facilities spent on a lease contract basis.

Depreciation and amortization (Millions of yen) 2013 Year ended March 31 2008 2009 2010 2011 2012 Forecast 1,635 1,822 1,701 1,532 1,400 1,290 Manufacturing cost Selling, general and 626 622 556 512 553 640 administrative expenses R&D expenses 1.091 946 945 762 764 910 Others 0 3,353 3,391 3,202 2,808 2,717 Consolidated 2,840

■Lease expenses (Millions of yen) 2013 2008 2009 2010 2011 2012 Year ended March 31 Forecast 1,042 931 527 156 23 20 Consolidated 925 437 2 2 Manufacturing cost 821 94

■Number of employees

Year ended March 31	2008	2009	2010	2011	2012
Consolidated	2,483	2,690	2,756	2,867	3,053
Sales division	907	1,007	1,048	1,108	1,268
Production division	798	828	838	847	860
R&D division	519	541	557	574	624
Corporate or back-office division	259	314	313	338	301

Forecasts in this report are based on the currently available information. Actual results may differ materially depending on a number of factors including adverse economic conditions etc.

Reference information Research & development

■ Pipeline of prescription pharmaceuticals (Clinical Stage)

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched		
				Japan		Dec						
		Glaucoma/	Co-development	Europe		J						
Tafluprost	DE-085		with Asahi Glass	U.S.	(Licensed Out)					Mar-12		
		Ocular hypertension		Latin America	(Licens	sed Ou	t)		1	Aug-10		
				China				Jan-12				
Prostaglandin F _{2α} derivativ	ve for the treatm	ent of glaucoma and ocular hyperte	nsion. Launched in Japa	an in Dece	mber, 20	008. In I	Europe,	it is mark	keted in			
Germany, Denmark, etc.	In the U.S., dev	elopment rights were granted to Me	rck & Co., Inc. (U.S.) in A	pril, 2009.	In Asia	i, it is ma	arketed	in Hong k	Kong, Ko	rea,		
Indonesia, Singapore, ND	A filed in China.	In US, NDA approval obtained in F	ebruary, 2012 and launch	ned in Mar	ch, 2012	2 by Mer	ck and	Co., Inc.				

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
Diquafosol sodium	DE-089		Inspire (Merck)	Japan	an Dec-1					
		Dry eye	inspire (merck)	Asia					Dec-11	

A dry eye treatment drug which stimulates secretion of mucin and aqueous components from the corneal epithelium. Its mechanism of action is different from other existing treatments. Launched in Japan in December, 2010. Marketing approval was obtained in Korea, and NDA is under preparation in China.

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
Lomerizine HCI	DE-090	Glaucoma	MSD	Japan						

A new type of glaucoma treatment which inhibits the progression of visual field defects. It is the only calcium antagonist being development as an oral glaucoma treatment. Compared to NMDA receptor antagonists, systemic adverse drug reactions are mild and has excellent safety profile.

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
Rivoglitazone	DE-101	Corneal and conjunctival epithelial disorder associated with dry eye, etc.	Daiichi Sankyo	U.S.						

Based on its anti-inflammatory properties, quantitative and qualitative tear film improvement effect is expected.

Generic name	Dev. code	Indication	Original/Licensor	Region	P1 P2 P3			NDA Filed	Approved	Launched
Betamethasone	DE-102	Macular edema secondary to diabetes and BRVO*	Co-development with Oakwood	Japan	(P	(Phase 2/3)				

A steroid microsphere product with a new drug delivery concept. Stable and sustained efficacy is expected by injection around the affected area. Collaborating with Oakwood Laboratories (U.S.) for manufacturing technology development on commercial scale. *BRVO: Branch retinal vein occlusion.

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
(Undetermined)	DE-105	Persistent corneal	Original	U.S.						
	DE-105	epithelial defects	Original	Japan						

Expected to accelerate comeal epithelial migration and demonstrate high safety profile in treatment-resistant, persistent corneal epithelial defects.

			-							
Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
Levofloxacin (1.5%)	DE-108	Bacterial conjunctivitis	Daiichi-Sankyo	Japan	n					Jun-11
	DE 100	Dacterial conjunctivitis	Dalichi-Galikyo	Korea	Oct-1		Oct-11			

A high-concentration fluoroquinolone antibacterial agent. Launched in Japan in June 2011. NDA has been filed in Korea.

			icensor Region	 12	P3	NDA Fileu	Approved	Launche
Sirolimus	Sirolimus DE-109 Uveitis		U.S.					
Siloiinus DE-	DE-109 Uveitis		nal Japan					

Intravitreal injection with immunosuppressive effect, anti-angiogenic effect, etc. Phase 3 study is ongoing in US and Japan.

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
(Undetermined)	DE-110	Corneal and conjunctival epithelial disorder associated with dry eye, etc.	Original	U.S.						
A selective glucocorticoid receptor agonist (SEGRA) for the treatment of corneal and conjunctival epithelial disorders associated with dry eye, etc.										



Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launche
Tafluprost/	DE-111	Glaucoma/	Co-development with Asahi Glass	Japan						
timolol maleate	DE III	Ocular hypertension	Co-development	Europe						
combination drug of a pro	ostaglandin F2α deri									
Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launcher
Epinastine HCI	DE-114	Allergic conjunctivitis	Nippon Boehringer Ingelheim	Japan		12	10			
An H1 receptor antagonist	with membrane-sta	bilizing function, as treatment for all	ergic conjunctivitis.							
			- F						1	
Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launche
Tafluprost	DE-118	Glaucoma/ Ocular hypertension	Co-development with Asahi Glass	Japan			Fe	eb-2012		
Prostaglandin F2α derivativ	re for the treatment	of glaucoma and ocular hypertensio	n. Preservative-free, unit-dose	, single-use	e type p	oduct.				
Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launche

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	J Launcheo
(Undetermined)	DE-098 (Anti-APO-1 antibody)	Rheumatoid arthritis	Janssen Biotech	Japan						
Joint injection inducing apo	ptosis in diseased	joints of rheumatoid arthritis patients.								

■Novagali's pipeline of prescription pharmaceuticals (Clinical Stage)

Generic name	Dev. name	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launche		
		Severe dry eye	Original	Europe								
Ciclosporin	Cyclokat	Severe dry eye	Onginal	U.S.								
-			Fopical ophthalmic emulsion which improves symptoms and signs of severe dry eye by immunosuppressive effect. Cationic emulsion technology has enhanced ocular tissue absorption.									
		Vernal Keratoconjunctivitis	Original	Europe								
Ciclosporin	Vekacia	Topical ophthalmic emulsion which in emulsion technology has enhaned or		ctivitis sym	ptoms b	y immun	osuppre	ssive eff	ect. Cati	ionic		
Latanoprost	Catioprost	Glaucoma/ Ocular hypertension	Original	Europe								
		Topical ophthalmic emulsion of a pro	staglandin \mathbb{P}_{α} derivative, for	the treatm	ent of gla	aucoma	and ocu	lar hyper	tension.			
Dexamethasone	Cortiject	Diabetic macular edema	Original	U.S.	(Phas	se 1/2)						
Palmitate	,	Intravitreal injection with anti-inflammatory effect.										

*Catioprost and Cortiject are under project evaluation.

Changes from February 7, 2012

Dev. code	Changes
DE-085	Marketing approval obtained, launched (U.S.)
DE-089	NDA filed (China)
DE-098	Completed Phase 2 study
DE-110	Completed Phase 2 study
DE-112	Development discontinued (Santen judged it cannot meet the expected achievement criteria)
Vekacia	Development continued (Phase 3 stage)

Pharmaceutical market in Japan

Revision of N	lational	Health	Insuran	ce (NH	l) drug p	orices					(%)
	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Industry average	-6.3	—	-4.2	—	-6.7	_	early -5%	_	mid -6%	_	-6.25
Ophthalmic drugs	-6.0	_	-2.7	_	-5.5	_	late -3%	_	early -3%	_	mid -4%
Santen	-6.0	_	-3.2	_	-5.3	_	mid -3%	_	mid -5%	_	late -5%
									(Compiled	by Santen)

Revision of NHI drug prices:

In Japan, drug prices are generally revised every two years to reflect their market price. The drugs marketed at lower market prices will bear larger reduction margins at the revision.

■Market shares

					(Billions of yen)
Year ended March 31	2008	2009	2010	2011	2012
Descention on hthe lowice	38.9%	38.0%	37.3%	35.8%	36.1%
Prescription ophthalmics	221.0	226.9	234.9	247.4	254.9
Anti-rheumatic drugs	46.1%	45.0%	43.9%	43.0%	41.0%
(DMARDs*)	24.1	24.8	25.7	25.5	27.2

Notes: - On an NHI drug price basis.

- Lower figures indicate market size.

*Anti-rheumatic drugs exclude biologic agents.

Copyright IMS Japan KK, 2012 Source: Santen analysis based on IMS data(JPM) Period: 2007.4-2012.3; Unauthorized copy prohibited

Market shares by therapeutic area - prescription ophthalmics

_	-		-		(Billions of yen)
Year ended March 31	2008	2009	2010	2011	2012
Anti-glaucoma	20.8%	20.3%	23.0%	25.7%	28.4%
-	83.2	85.0	88.5	90.1	92.2
Corneal disease treatments	78.7%	77.7%	77.1%	76.0%	77.5%
	28.9	30.5	31.7	32.0	35.6
Anti-infection	72.4%	70.9%	70.0%	68.4%	67.5%
	24.4	23.7	22.6	22.4	21.5
Anti-allergy	22.7%	21.0%	19.8%	16.7%	17.6%
	25.4	28.2	24.0	29.3	26.4

Notes: - On an NHI drug price basis.

- Lower figures indicate market size.


Copyright IMS Japan KK, 2012

Source: Santen analysis based on IMS data(JPM) Period: 2007.4-2012.3; Unauthorized copy prohibited

Stock information



Stock price (Osaka Securities Exchange 1st market) (Yen and thousand shares) Apr-11 May-11 Jun-11 Jul-11 Aug-11 Sep-11 Oct-11 Nov-11 Dec-11 Jan-12 Feb-12 Mar-12 Stock price: 3,240 End of month 3,125 3,260 3,100 3,035 3,240 2,930 2,901 3,170 3,120 3,215 3,535 Volume 5,573 4,052 4,567 2,587 5,870 4,053 5,417 6,206 4,915 4,039 3,657 4,272



Major shareholders	As o	of March 31, 2012
Name	Number of	Percentage of
Manie	shares held	investment
	Thousand shares	%
Japan Trustee Service Bank, Ltd.	11,424	13.1
Mita Sangyo Co., Ltd.	4,756	5.5
State Street Bank and Trust Company 505223	3,776	4.3
The Master Trust Bank of Japan, Ltd.	3,456	4.0
Development Bank of Japan Inc.	3,310	3.8
Nippon Life Insurance Company	2,717	3.1
The Bank of Tokyo-Mitsubishi UFJ, Ltd.	2,120	2.4
Trust & Custody Services Bank, Ltd.	2,065	2.4
Mellon Bank Treaty Clients Omnibus	1,994	2.3
RBC dexia investor services trust,London-lending account	1,984	2.3

■ Major stock information

Year ended March 31	2008	2009	2010	2011	2012
Issued shares (thousands)	86,866	86,916	86,992	87,053	87,146
Treasury stock (thousands)	1,888	1,893	1,902	0	1
Market Capitalization (million)	197,573	232,961	238,763	288,579	308,059
A purchased amount of money (millions of yen)	4,800	_	_	_	_
The number of the purchased stocks (thousand shares)	1,833	_	_	_	_


Stock information


Breakdown of shareholding by number of shares

Year ended March 31	200)8	200)9	201	10	201	11	201	12
	Thousand	Propor-								
	shares	tion (%)								
Financial institutions	33,186	38.2	36,226	41.6	32,693	37.6	32,284	37.1	30,457	35.0
City & regional banks	4,907	5.6	4,794	5.5	2,558	2.9	2,422	2.8	2,376	2.7
Trust banks	19,133	22.0	23,714	27.3	22,466	25.8	20,431	23.5	19,316	22.2
(concerned in trust works)	16,680		21,167		19,948		18,310		16,923	
Life and non-life insurance	8,924	10.3	7,254	8.3	7,022	8.1	5,274	6.0	4,740	5.4
Other financial institutions	221	0.3	462	0.5	645	0.7	4,155	4.8	4,023	4.6
Securities firms	585	0.7	526	0.6	518	0.6	417	0.5	375	0.4
Other institutions	13,014	15.0	13,071	15.0	13,392	15.4	13,413	15.4	12,098	13.9
Foreign investors	25,227	29.0	23,679	27.3	27,553	31.7	31,228	35.9	35,130	40.3
Individual investors	12,963	14.9	11,516	13.3	10,931	12.6	9,708	11.1	9,083	10.4
Treasury stock	1,888	2.2	1,893	2.2	1,902	2.2	0	0.0	1	0.0
Total	86,866	100.0	86,916	100.0	86,992	100.0	87,053	100.0	87,146	100.0

Breakdown of shareholding by number of shareholders

Year ended March 31	200)8	200)9	201	10	201	1	201	12
	Number of	Propor-	Number of	Propor-	Number of	Propor-	Number of	Propor-	Number of	Propor-
	shareholders	tion (%) s	shareholders	tion (%) s	hareholders	tion (%)	shareholders	tion (%)	shareholders	tion (%)
Financial institutions	88	0.6	81	0.7	81	0.7	71	0.8	63	0.8
City & regional banks	14	0.1	11	0.1	8	0.1	6	0.1	5	0.1
Trust banks	30	0.2	26	0.2	29	0.2	28	0.3	28	0.3
Life and non-life insurance	29	0.2	33	0.3	34	0.3	29	0.3	26	0.3
Other financial institutions	15	0.1	11	0.1	10	0.1	8	0.1	4	0.1
Securities firms	38	0.3	36	0.3	41	0.4	32	0.3	33	0.4
Other institutions	150	1.2	137	1.2	127	1.2	125	1.4	121	1.5
Foreign investors	268	2.1	355	3.2	366	3.4	381	4.2	360	4.3
Individual investors	12,568	95.8	10,570	94.6	10,296	94.4	8,479	93.3	7,710	93.0
Treasury stock	1	0.0	1	0.0	1	0.0	1	0.0	1	0.0
Total	13,113	100.0	11,180	100.0	10,912	100.0	9,089	100.0	8,288	100.0





Consolidated subsidiaries



[Domestic]

[Domestic]										
Claire Co., Ltd.										
Main business	Cleaning of antidust and ster									
Location	Shiga, Japan	Paid-in capital	90 million yen	Equity owned	100%					
[Overseas]										
Santen Holdings	U.S. Inc.									
Main business	Holding company for North	American business	es and business development							
Location	California, U.S.A.	Paid-in capital	24,784 thousand US\$	Equity owned	100%					
Santen Inc.										
Main business	Clinical development and business development of pharmaceuticals									
Location	California, U.S.A.	Paid-in capital	8,765 thousand US\$	Equity owned	100%*					
Advanced Vision										
Main business	Research and development,	-								
Location	California, U.S.A.	Paid-in capital	10 thousand US\$	Equity owned	100%*					
Santen Holdings	EU B.V.									
Main business	Holding company for Europ	ean operation								
Location	Amsterdam, Netherlands	Paid-in capital	50 thousand euros	Equity owned	100%					
Conton Ov										
Santen Oy Main business	Development, production an	d markating of pha	rmacauticals							
Location	Tampere, Finland	Paid-in capital	20,000 thousand euros	Equity owned	100%					
Location	Tampere, Filliand	Faiu-III Capitai	20,000 mousaila euros	Equity Owned	100%					
SantenPharma A	٨B									
Main business	Marketing support of pharm	aceuticals								
Location	Stockholm, Sweden	Paid-in capital	500 thousand S.KR	Equity owned	100%					
Santen GmbH										
Main business	Marketing of pharmaceutica	ls and business dev	elonment							
Location	Germaring, Germany	Marketing of pharmaceuticals and business development Germaring, Germany Paid-in capital 25 thous			100%					
Location	Germanig, Germany	1 ald-III capital	25 thousand curos	Equity owned	10070					
Novagali Pharma	a SAS									
Main business	Development and marketing		3							
Location	Evry, France	Paid-in capital	1,305 thousand euros	Equity owned	100%					
Santen Pharmar	eutical (China) Co., Ltd.									
Main business	Development, production an	d marketing of pha	rmaceuticals							
Location	Suzhou, China	Paid-in capital	3,300 million yen	Equity owned	100%					
				1						
Santen Pharmac	ceutical Korea Co., Ltd.									
Main business	Import and marketing of pha									
Location	Seoul, Korea	Paid-in capital	9,000,000 thousand won	Equity owned	100%					
Taiwan Cantar F	Dearmonouting! On 1td									
Main business	Pharmaceutical Co., Ltd. Import and marketing of pha	rmacouticala								
Location	Taipei, Taiwan	Paid-in capital	42,000 thousand Taiwan dollars	Equity owned	100%					
Location		r alu-in capital		Equity Owned	100%					
Santen India Priv	vate Limited									
Main business	Market research for pharmac	centicals								
Wiam Ousmess	Market research for pharma	councuis								

* Indirect investment through Santen Holdings U.S. Inc.

News releases

News releases during April 2011-March 2012

For details, please refer to our Web site (http://www.santen.com).

2011

14-Apr Santen Inc. Head Office Relocation

Santen announced the relocation of Santen Inc., its U.S. subsidiary, newly in Emeryville, California, U.S.A. As Santen Group's vital research & development base in North America, Santen Inc. will accelerate conducting clinical development and business development activities to enhance the Group's product pipeline.

Santen completed its relocation in July, 2011.

10-May Medium Term Management Plan FY2011-2013

Santen announced a 3 Year Medium Term Management Plan (hereinafter "MTP") for FY2011-2013, aiming to become a "Specialized Pharmaceutical Company with a Global Presence." Santen's long term strategic vision is to become one of the top ophthalmic pharmaceutical companies in the world by the year 2020.

In order to further reinforce its competitiveness, Santen will make investments during the new MTP period to strengthen its US-centered global clinical trials system and enhance business development activities. In addition, Santen will accelerate its business activity in high-growth markets in Europe and China.

10-May Santen to Issue Stock Acquisition Rights to the Directors for the Purpose of Granting Stock Options

Santen to Issue Stock Acquisition Rights to the Corporate Officers for the Purpose of Granting Stock Options

2-Jun Santen Launches Broad-spectrum Antibacterial Ophthalmic Solution, Cravit Ophthalmic Solution 1.5%

2-Aug Notice on the Establishment of Subsidiary in India

Santen announced that it has established its subsidiary, Santen India Private Limited in India on July 29, 2011. Santen has decided to establish a local entity in India, in order to spread the "Santen" brand with a view to establish its presence in the Indian ophthalmic market with strong growth potential. In the initial stage, however, we will mainly focus on exploring business opportunities including product development and production areas.

28-Sep Signing of an agreement with respect to an acquisition of a controlling interest in Novagali Pharma by Santen

Santen and Novagali Pharma (hereafter "Novagali"), a French biopharmaceutical company specializing in ophthalmology and focusing on new ocular therapeutics, announced that Santen and Novagali entered into a share purchase agreement, whereby Santen should acquire shares representing 50.55% of the share capital of Novagali. Santen aims to strengthen its global business platform by acquiring Novagali with its R&D capability represented by its unique pharmaceutical technologies, and a unique pipeline product for dry eye in a late development stage in Europe.

Santen completed the acquisition of a controlling interest in Novagali as of October 11, 2011, and Novagali became wholly-owned subsidiary by Santen as of January 6, 2012.



2011

14-Oct Ube and Santen Announce License and Collaboration Agreement for EP2 Agonist

Ube Industries, Ltd. (hereafter "Ube") and Santen announced that they have entered into a license and collaboration agreement with regard to Ube's EP2 agonist compound as an ophthalmic treatment drug (development code: DE-117). The Agreement provides Santen with global rights to develop, manufacture and commercialize DE-117. Ube and Santen have agreed to co-develop DE-117 as a treatment drug for glaucoma and ocular hypertension, and will collaborate in developing the compound as a prostaglandin drug product with a new mechanism of action. The goal is to obtain manufacturing and marketing approval on a worldwide scale.

2012

23-Jan Santen to Launch Nutritional Supplement Sante Lutax 20 + DHA

7-Feb Notice on the Establishment of Holding Company in Europe

Santen announced that it will establish Santen Holdings EU B.V. ("Santen EU") in the Kingdom of Netherlands. Santen EU will be established as a holding company of Santen's existing subsidiaries in Europe, which will overlook Santen's European business. Santen aims to strengthen its European business by creating a more efficient and effective governance system by concentrating the financial control functions of Santen's European operation. Santen executed its establishment in March, 2012.

14-Feb FDA Approves *ZIOPTAN* (tafluprost ophthalmic solution), Merck's Once-Daily, Preservative-Free Ophthalmic Medication for Glaucoma

1-Mar Santen to Launch Sante Medical Guard OTC Eye Drop

